VXRT - Dosing underway for Vaxart's early-stage COVID-19 oral vaccine trial

The company has dosed the first subject in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. (VXRT) shares are up 6% in premarket in reaction to the news.The 48-subject study will examine the safety and immunogenicity of two doses of VXA-CoV2-1 in healthy adult volunteers aged 18 to 54 years old. Enrollment is expected to be completed by early November, with participants receiving the low or high dose of the VXA-CoV2-1 oral tablet at days 1 and 29. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the active phase.Anticipates to first clinical data in the next few weeks.

For further details see:

Dosing underway for Vaxart's early-stage COVID-19 oral vaccine trial